Additionally, we demonstrated that the combination of the alkylating agent trabectedin and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor olaparib exhibits antitumor activity against a subset of sarcomas in both preclinical and clinical studies [10, 11]. This evidence concerns the gene PARP1 and sarcoma.